Last reviewed · How we verify
NCT04990934
Transitioning Care: Perspectives of Older Women With Early Breast Cancer on Current Telemedicine Modalities
trial testing Semistructured Interview in Breast Cancer Female in 15 participants. Completed in 10 October 2021.
10 October 2021
Quick facts
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 2 July 2021 |
| Primary completion | 10 October 2021 |
| Estimated completion | 10 October 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Semistructured Interview
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
UNC Lineberger Comprehensive Cancer Center — full company profile →
Who can join
Adults 65 to 110, female only, with Breast Cancer Female or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Explosive growth in the use of telemedicine (video or telephone visits) has followed the onset of the coronavirus disease 2019 (COVID-19) pandemic in order to meet healthcare needs while avoiding unnecessary exposure risks in ambulatory care spaces. Accordingly, in March 2020, the Centers for Medicare \& Medicaid Services expanded reimbursement for telemedicine visits to equal that of in-person services. The policy and infrastructure that enabled this emergency transition is laying the groundwork for enduring expansion of elective telemedicine, a technology that could significantly decrease the burden of medical care in older patients with cancer. To benefit from telehealth, patients must have a certain level of knowledge and capacity to engage with technology, which can be a challenge for some older adults because of inexperience, access, and disability. As cancer is mainly a disease of older adults, with a median age of 65 at diagnosis for most cancer types, this is a significant limitation on the utility of telemedicine in oncology. The goal of our study is to better understand older breast cancer patients' experiences with telephone and video telemedicine with regard to visit convenience, completeness, and interpersonal satisfaction through semi-structured interviews with patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Perspectives of older women with early breast cancer on telemedicine during post-primary treatment.
Buse CR, Kelly EAO, Muss HB, Nyrop KA. · · 2022 · cited 8× · PMID 36378342 · DOI 10.1007/s00520-022-07437-0
Verify or expand the search:
- PubMed search for NCT04990934
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other UNC Lineberger Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06656936 — The PharmFIT Study · NA · not yet recruiting
- NCT05937659 — Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT · not yet recruiting
- NCT07479199 — Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors · not yet recruiting
- NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · Phase 2 · recruiting
- NCT04266730 — Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04990934 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center
- Last refreshed: 9 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04990934.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing